Group One Trading
RLMD icon

Group One Trading’s Relmada Therapeutics RLMD Stock Holding History

Group One Trading’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$268K Sell
38,700
-45,200
-54% -$316K ﹤0.01% 4054
2026
Q1 		$584K Sell
83,900
-93,500
-53% -$442K ﹤0.01% 3201
2025
Q4 		$857K Buy
177,400
+121,600
+218% +$407K ﹤0.01% 3037
2025
Q3 		$112K Buy
55,800
+31,500
+130% +$30.2K ﹤0.01% 5228
2025
Q2 		$14.6K Sell
24,300
-48,400
-67% -$24.8K ﹤0.01% 6472
2025
Q1 		$19.6K Sell
72,700
-40,700
-36% -$13.5K ﹤0.01% 5820
2024
Q4 		$59K Sell
113,400
-47,600
-30% -$116K ﹤0.01% 4933
2024
Q3 		$522K Buy
161,000
+158,900
+7,567% +$515K ﹤0.01% 2823
2024
Q2 		$6.3K Sell
2,100
-49,300
-96% -$178K ﹤0.01% 5850
2024
Q1 		$239K Buy
51,400
+25,200
+96% +$121K ﹤0.01% 3403
2023
Q4 		$108K Buy
26,200
+21,200
+424% +$62.8K ﹤0.01% 4395
2023
Q3 		$15K Sell
5,000
-8,300
-62% -$24.7K ﹤0.01% 6100
2023
Q2 		$32.7K Sell
13,300
-7,000
-34% -$19.4K ﹤0.01% 5614
2023
Q1 		$45.9K Sell
20,300
-274,000
-93% -$945K ﹤0.01% 4914
2022
Q4 		$1.03M Sell
294,300
-152,100
-34% -$1.34M ﹤0.01% 2381
2022
Q3 		$16.5M Buy
446,400
+389,700
+687% +$10.8M 0.03% 480
2022
Q2 		$1.08M Sell
56,700
-34,200
-38% -$746K ﹤0.01% 2680
2022
Q1 		$2.45M Buy
90,900
+23,200
+34% +$480K ﹤0.01% 2204
2021
Q4 		$1.52M Sell
67,700
-100
-0.1% -$2.22K ﹤0.01% 2899
2021
Q3 		$1.78M Buy
67,800
+62,500
+1,179% +$1.67M ﹤0.01% 2789
2021
Q2 		$170K Sell
5,300
-3,300
-38% -$115K ﹤0.01% 5405
2021
Q1 		$303K Sell
8,600
-1,400
-14% -$49K ﹤0.01% 4563
2020
Q4 		$321K Sell
10,000
-2,200
-18% -$75.6K ﹤0.01% 3681
2020
Q3 		$459K Buy
12,200
+10,900
+838% +$421K ﹤0.01% 2917
2020
Q2 		$58K Buy
1,300
+1,200
+1,200% +$50.7K ﹤0.01% 4263
2020
Q1 		$3K Hold
100
– – ﹤0.01% 4903
2019
Q4 		$4K Buy
+100
New +$3.04K ﹤0.01% 4799

Other funds holding RLMD

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JHC
Jones Hill Capital New York $470M AUM
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Group One Trading's RLMD Position: Q2 2026 in Review

Group One Trading sold out of Relmada Therapeutics (RLMD) in Q2 2026, closing a stake of 14,350 shares — an estimated $100K sold.

Group One Trading first reported a position in RLMD in Q1 2021 and held it in 16 quarters. The position peaked at $857K in Q1 2024. 126 funds tracked by Wall St. Rank hold RLMD as of Q2 2026.

  • Group One Trading reported no remaining Relmada Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Group One Trading sold 14,350 Relmada Therapeutics shares in Q2 2026, an estimated $100K.
  • Group One Trading first reported a position in Relmada Therapeutics in Q1 2021 and held it in 16 quarters.
  • Group One Trading's Relmada Therapeutics position peaked at $857K in Q1 2024.
  • 126 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q2 2026.

Based on Group One Trading's 13F filing for Q2 2026, filed 14 Aug 2026.